Last updated: August 1, 2026
Lialda is a mesalamine extended-release tablet for induction and maintenance of remission in adults with ulcerative colitis. Its commercial profile is defined by a mature product, broad generic availability, limited remaining patent protection, and continuing demand within a large chronic gastrointestinal market. The investment case is no longer based on Lialda as a protected growth asset. It depends on manufacturing efficiency, portfolio synergies, brand retention, payer positioning, and the durability of the mesalamine market.
Takeda acquired Lialda through its 2019 acquisition of Shire. The product was originally developed and commercialized by Shire. Generic competition has materially reduced the product's exclusivity value, although Lialda retains clinical recognition and remains differentiated from some mesalamine products through once-daily dosing and its MMX extended-release delivery system. [1][2]
What is Lialda and how does it work?
Lialda is the branded version of mesalamine, also called 5-aminosalicylic acid or 5-ASA. It is administered orally as an extended-release tablet.
| Attribute |
Lialda profile |
| Active ingredient |
Mesalamine |
| Brand owner |
Takeda Pharmaceutical Company |
| Original developer |
Shire |
| FDA approval |
January 2007 |
| Dosage form |
Delayed-release, extended-release tablet |
| Strengths |
1.2 g tablet |
| Indication |
Induction and maintenance of remission in adults with ulcerative colitis |
| Typical induction dose |
2.4 g to 4.8 g once daily |
| Typical maintenance dose |
2.4 g once daily |
| Delivery technology |
MMX multi-matrix extended-release system |
| Regulatory category |
Small-molecule prescription drug |
| Biosimilar exposure |
None |
Mesalamine acts locally in the colon and is not an immunosuppressive biologic. Its safety profile and long clinical history support continued use in mild-to-moderate ulcerative colitis, particularly before escalation to corticosteroids, immunomodulators, biologics, or small-molecule immunotherapies. [1]
What patents protect Lialda?
Lialda's original patent estate covered the mesalamine formulation, controlled release, and delivery architecture rather than a novel active pharmaceutical ingredient. The active ingredient, mesalamine, has been used clinically for decades and is not itself a durable composition-of-matter asset.
The principal commercial protection centered on the MMX formulation and related controlled-release technology. Public FDA and court records identify several patents associated with Lialda and its generic challenges, including patents in the U.S. Patent No. 6,773,720 family and later formulation-related patents. The exact Orange Book listing can change as patents expire, are delisted, or are superseded. [3][4]
What formulations are protected by Lialda patents?
The protected subject matter generally involved:
- A high-dose mesalamine tablet.
- Delayed release until the dosage form reaches the terminal ileum and colon.
- A hydrophilic and lipophilic matrix designed to control drug release.
- Once-daily administration.
- Delivery of mesalamine throughout the colon.
This formulation-based protection was commercially meaningful when Lialda entered the market. It did not create long-term ingredient exclusivity because competing manufacturers could develop alternative mesalamine dosage forms, release mechanisms, or tablet designs.
How strong is the Lialda patent estate?
The estate is weak as a current investment moat because the core patents have reached or passed their practical exclusivity period and generic manufacturers have obtained FDA approvals. The technical formulation remains differentiated, but differentiation is no longer equivalent to enforceable market exclusivity.
| Patent-estate factor |
Assessment |
| Active ingredient protection |
None of material current value |
| Formulation protection |
Historically important; largely eroded |
| Method-of-use protection |
Limited commercial impact |
| Manufacturing barriers |
Moderate, but not prohibitive |
| Generic substitution risk |
High |
| Biosimilar risk |
Not applicable |
| Litigation leverage |
Low after generic approvals |
| Current patent moat |
Weak |
When did Lialda lose exclusivity?
Lialda lost meaningful U.S. market exclusivity after FDA approval of generic mesalamine extended-release tablets. The FDA approved a generic version of Lialda in 2017, and additional manufacturers entered the market thereafter. [5]
The relevant distinction is between formal patent expiration and practical commercial exclusivity:
| Event |
Approximate timing |
Commercial effect |
| Lialda FDA approval |
2007 |
Brand launch |
| New chemical entity exclusivity |
Expired in 2012 |
No continuing NCE protection |
| Generic Lialda approval |
2017 |
Formal generic competition |
| Additional generic entry |
2017 onward |
Price and share pressure |
| Current status |
Mature generic market |
Brand operates without broad exclusivity |
The Hatch-Waxman framework gave Lialda a period of market protection after approval, but the product's commercial life extended beyond that period because formulation complexity, physician familiarity, and payer dynamics delayed complete erosion. [6]
What is the Orange Book status of Lialda?
Lialda has historically been listed in the FDA Orange Book with formulation-related patents. The Orange Book identifies patents and exclusivity information submitted by the applicant for approved drug products. It does not establish that every listed patent remains commercially enforceable against every generic product. [3]
A current diligence review should distinguish:
- Listed patents for the reference product.
- Patent expiration dates.
- Pediatric exclusivity.
- Generic product labeling.
- Paragraph IV certifications.
- Whether a generic manufacturer launched at risk or after litigation resolution.
For Lialda, the commercial significance of the Orange Book is primarily historical. The presence of formulation patents did not prevent generic entry after the relevant patent and regulatory barriers were overcome.
Which companies challenged Lialda patents?
Generic manufacturers challenged or sought approval to market mesalamine extended-release products. Publicly reported participants included Zydus Pharmaceuticals and other generic manufacturers operating in the mesalamine category. Generic competition has also included products marketed under abbreviated new drug applications rather than branded Lialda licensing arrangements. [5][7]
What were the Paragraph IV risks?
Paragraph IV certifications are used when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger patent litigation and a potential 30-month stay of FDA approval under the Hatch-Waxman Act.
For Lialda, Paragraph IV activity created a finite litigation window. Once generic approvals were granted and multiple suppliers entered, the value of additional patent challenges declined. A generic entrant no longer needed to solve the entire market-access problem if competing products had already established an abbreviated regulatory pathway and payer substitution had begun.
What is Lialda's FDA regulatory status?
Lialda remains an FDA-approved prescription treatment for adults with ulcerative colitis. Its label includes dosing for induction and maintenance of remission. The product is a small molecule and does not require the biologic licensing pathway used for infliximab, adalimumab, ustekinumab, vedolizumab, or other biologic therapies. [1]
| Regulatory issue |
Lialda status |
| FDA approval |
Active |
| Reference product |
Yes |
| ANDA competition |
Yes |
| Biologic license |
No |
| Biosimilar pathway |
Not relevant |
| Pediatric exclusivity |
Expired or no longer commercially material |
| Major safety restrictions |
Renal monitoring and hypersensitivity considerations |
| Clinical role |
Mild-to-moderate ulcerative colitis |
Mesalamine products require attention to renal function, hypersensitivity reactions, and formulation-specific labeling. The absence of biologic immunosuppression supports use in earlier-line treatment, but the product's market share is exposed to lower-cost generic alternatives and other mesalamine formulations. [1]
How many patents cover Lialda today?
The number of relevant patents depends on the jurisdiction, Orange Book snapshot, and whether expired or abandoned patents are included. A simple patent count is not a reliable measure of current protection.
For investment purposes, Lialda should be treated as having no material remaining U.S. composition-of-matter exclusivity and limited effective formulation exclusivity. The commercially relevant question is whether a specific generic product infringes a valid, enforceable patent. Generic approvals and market presence indicate that the historical patent estate does not block broad competition.
What generic entry risks exist for Lialda?
Generic entry risk is high and persistent. It affects both volume and net price.
The main erosion mechanisms are:
- Automatic or pharmacist-driven substitution where permitted.
- Payer preference for lower-cost mesalamine products.
- Formulary exclusion or higher copay tiers for branded Lialda.
- Generic contracting by wholesalers and pharmacy benefit managers.
- Prescriber willingness to switch stable patients.
- Therapeutic substitution among mesalamine formulations.
- Discounting required to preserve brand access.
Lialda can retain share among patients who respond well to its once-daily regimen or whose physicians prefer the MMX delivery system. That retention does not restore patent economics. It supports a residual branded market rather than a protected franchise.
What generic launch scenarios are most likely?
| Scenario |
Market outcome |
Investment implication |
| Broad generic substitution |
Rapid brand volume decline and net-price compression |
Lialda becomes a cash-flow harvesting asset |
| Limited generic contracting |
Brand retains selected plans and physicians |
Slower erosion, but lower margins |
| Product-specific supply disruption |
Temporary brand demand recovery |
Short-lived benefit |
| New generic entrants |
Further price pressure |
Higher risk to revenue |
| Clinical preference for once-daily dosing |
Brand share stabilizes in selected patients |
Supports residual premium |
| Reformulation or lifecycle product |
Potential defense of segment |
Requires regulatory and commercial investment |
How does Lialda compare with competing mesalamine drugs?
Lialda competes with both branded and generic mesalamine formulations. The principal alternatives include Apriso, Asacol HD, Delzicol, Pentasa, balsalazide, and sulfasalazine.
| Product |
Active ingredient |
Release or delivery profile |
Competitive position |
| Lialda |
Mesalamine |
MMX extended release; once daily |
Brand and generic competition |
| Apriso |
Mesalamine |
Extended release |
Maintenance-focused alternative |
| Delzicol |
Mesalamine |
Delayed-release capsule |
Competes on formulation and dose |
| Asacol HD |
Mesalamine |
Delayed-release tablet |
Mature product with generic exposure |
| Pentasa |
Mesalamine |
Controlled-release capsule |
Granule-based delivery |
| Balsalazide |
Balsalazide |
Colon-targeted prodrug |
Lower-cost alternative |
| Sulfasalazine |
Sulfasalazine |
Older systemic and colonic therapy |
Low-cost legacy treatment |
Lialda's strongest commercial differentiator is convenience. A once-daily regimen can support adherence relative to products requiring multiple daily doses. Its weakness is price: generic mesalamine products can deliver similar active therapy at substantially lower cost.
Lialda also competes indirectly with advanced ulcerative-colitis therapies. Biologics and oral small molecules are used in moderate-to-severe disease, but they do not eliminate the earlier-line market for mesalamine. Their commercial effect is strongest when patients fail or outgrow 5-ASA therapy.
What patent litigation affects Lialda?
The key litigation period involved challenges to Lialda formulation patents by generic manufacturers seeking FDA approval. These cases were part of the broader Hatch-Waxman process surrounding generic mesalamine products. The litigation risk was concentrated before generic entry and did not create a durable post-entry barrier.
For current investment analysis, the more important legal questions are:
- Whether any unexpired U.S. patent remains listed for the reference product.
- Whether a generic label includes the same indication and dosing.
- Whether a manufacturer is subject to a settlement or launch restriction.
- Whether a generic entered under a license or after patent expiration.
- Whether any state substitution restrictions apply.
The available commercial evidence supports treating Lialda as a post-litigation, post-exclusivity product. There is no biosimilar-style patent dance because Lialda is a conventional small molecule.
Were there licensing deals involving Lialda?
Lialda's principal ownership path was corporate rather than a currently visible standalone licensing thesis. Shire commercialized the product, and Takeda acquired Shire in 2019. The transaction transferred Lialda into Takeda's gastrointestinal portfolio alongside other gastroenterology products. [2]
The Shire-Takeda transaction matters because Lialda's value was assessed as part of a broader gastrointestinal franchise, not as an isolated protected asset. Portfolio ownership can preserve manufacturing, sales-force, and payer-contracting efficiencies even when a product has lost exclusivity.
What is Lialda's revenue exposure?
Takeda does not generally present Lialda as a separately reported high-growth segment in the way investors would assess a major launch product. Revenue is embedded within Takeda's gastrointestinal and mature-product portfolio reporting. [8]
The investment exposure has four components:
| Revenue driver |
Direction |
| Ulcerative-colitis prevalence |
Supports underlying demand |
| Generic substitution |
Reduces branded volume |
| Net price and rebates |
Reduces branded profitability |
| Once-daily product preference |
Supports residual share |
| Takeda manufacturing scale |
Supports cash generation |
| New product launches |
Determines portfolio replacement |
Lialda should be modeled as a declining or stable mature-product contributor rather than a growth engine. A reasonable scenario framework is:
- Bear case: rapid generic substitution, aggressive payer exclusion, and steep net-price erosion.
- Base case: gradual brand decline with a stable residual patient base and continued manufacturing contribution.
- Bull case: slower switching, favorable contracting, or supply constraints among generics temporarily preserve branded demand.
The base case does not require clinical failure. It requires only continued generic access and payer pressure.
How strong is the Lialda investment case?
Lialda has a durable disease market but a weak exclusivity profile.
Strengths
- Established FDA-approved therapy.
- Large and persistent ulcerative-colitis patient population.
- Long clinical history.
- Once-daily dosing advantage.
- No biosimilar replacement risk.
- Potential manufacturing and portfolio synergies for Takeda.
- Lower clinical complexity than advanced immunotherapies.
Weaknesses
- Generic extended-release mesalamine competition.
- No meaningful active-ingredient exclusivity.
- Formulation patents have limited current blocking power.
- Payer pressure on branded pricing.
- Limited potential for major volume growth.
- Competition from multiple mesalamine dosage forms.
- Patient migration to biologics or small molecules in refractory disease.
Investment interpretation
Lialda is more valuable as a cash-flow and portfolio-management asset than as an intellectual-property growth asset. Its residual value depends on brand persistence, supply reliability, physician familiarity, and Takeda's ability to manage cost of goods and commercial overhead.
A valuation model should avoid assigning a long-duration brand premium. The key variables are:
- Annual branded prescription decline.
- Net price decline after rebates.
- Generic share penetration.
- Gross margin after manufacturing and distribution costs.
- Remaining promotional spending.
- Patient retention associated with once-daily dosing.
- Takeda's ability to replace Lialda revenue with newer gastrointestinal products.
What generic launch risks should investors monitor?
The most relevant indicators are:
- New ANDA approvals for mesalamine extended-release tablets.
- Additional manufacturers entering pharmacy networks.
- Formulary exclusions for branded Lialda.
- Changes in average wholesale price and net realized price.
- Declining branded prescription volume.
- Changes in Takeda's gastrointestinal portfolio disclosures.
- Product recalls or supply interruptions affecting generic competitors.
- New clinical guidelines that reduce or expand mesalamine use.
- Patent delistings or Orange Book changes.
- Litigation settlements that alter launch timing.
Generic supply disruption can temporarily benefit the brand, but it is not a durable investment thesis. Persistent brand value requires clinical preference or contracting advantages.
What geographic coverage protects Lialda?
The strongest commercial history is in the United States, where the brand, Orange Book, and Hatch-Waxman framework shaped market access. Patent rights and generic entry are jurisdiction-specific.
| Region |
Key issue |
| United States |
FDA approval, Orange Book patents, ANDA competition |
| European Union |
National and centralized regulatory procedures; formulation and market rights vary |
| Japan |
Separate regulatory review and reimbursement environment |
| Emerging markets |
Local registration, pricing controls, and generic manufacturing |
| Global |
Patent rights, trademarks, and regulatory exclusivity differ by country |
U.S. patent expiration does not automatically determine foreign market status. For multinational diligence, each jurisdiction requires separate review of formulation patents, regulatory data exclusivity, trademarks, and local generic approvals.
What manufacturing and intellectual-property barriers remain?
Manufacturing Lialda is more complex than producing an immediate-release mesalamine tablet because the product must deliver a high drug load through a controlled-release matrix. Relevant barriers include:
- Consistent tablet compression at high dose.
- Coating and release-control uniformity.
- Stability across storage conditions.
- Dissolution performance across gastrointestinal pH conditions.
- Bioequivalence or comparative performance requirements.
- Reliable supply of excipients and manufacturing capacity.
These barriers can limit the number of successful generic manufacturers, but they do not restore patent exclusivity. Once multiple manufacturers qualify, the formulation becomes a competitive manufacturing problem rather than a protected technology platform.
Key Takeaways
- Lialda is Takeda's branded mesalamine extended-release tablet for ulcerative colitis.
- FDA approval occurred in 2007, and generic competition began in 2017.
- The historical patent estate focused on MMX controlled-release formulation technology.
- Lialda has no meaningful current composition-of-matter moat.
- Generic and therapeutic competition creates high ongoing erosion risk.
- Once-daily dosing and physician familiarity can preserve residual brand share.
- Biosimilar risk is irrelevant because Lialda is a conventional small molecule.
- Lialda should be valued as a mature cash-flow asset, not a protected growth product.
- The most important diligence metrics are branded prescription decline, net price, generic share, gross margin, and Takeda's portfolio replacement strategy.
FAQs About Lialda Patent and Investment Risk
Is Lialda still under patent protection?
Lialda's historical protection centered on formulation and controlled-release patents. Generic approvals and market entry indicate that those patents no longer provide broad commercial exclusivity in the United States.
Is generic mesalamine the same as Lialda?
Generic products contain mesalamine, but release mechanisms, tablet design, dosing instructions, and approved labels can differ. FDA-approved generic extended-release products are intended to be therapeutically substitutable under applicable law.
Can a biosimilar replace Lialda?
No. Lialda is a small-molecule drug, not a biologic. Competition comes through ANDA-approved generics and alternative mesalamine formulations.
Does once-daily dosing protect Lialda from generic competition?
Once-daily dosing can support adherence and brand retention, but it does not prevent generic substitution where an approved generic has a comparable formulation and label.
Is Lialda a growth product for Takeda?
Lialda is better characterized as a mature gastrointestinal product. Its future value depends on residual brand demand, pricing, manufacturing efficiency, and its role within Takeda's broader gastroenterology portfolio.
References
- U.S. Food and Drug Administration. (2024). Lialda (mesalamine) delayed-release tablets prescribing information.
- Takeda Pharmaceutical Company Limited. (2019). Acquisition of Shire plc: Transaction completion materials.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Patent and Trademark Office. (2024). Patent Center and patent assignment records for mesalamine extended-release formulations.
- U.S. Food and Drug Administration. (2017). FDA approves first generic version of Lialda.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. ยง 355.
- U.S. District Court records. (2008-2017). Hatch-Waxman litigation involving mesalamine extended-release tablets and Lialda-related patents.
- Takeda Pharmaceutical Company Limited. (2024). Annual report and consolidated financial results.
